Biosergen AB announced a change in management from 31 January 2024 when Peder M. Andersen will step down from his current role as CEO and transition into a Chief Medical Officer role in Biosergen. Peder M. Andersen has served as CEO of the company for the past six and a half years and will remain committed to the company in his new role and ensure a smooth transition. Biosergen has evolved significantly under the leadership of Peder M. Andersen.

Key highlights were the IPO in 2021, the first GMP-manufactured compound in 2019, Orphan Drug Designation in the USA for Aspergillosis in 2019, initiation of the project to nanoformulation of BSG005, completion of phase 1 in healthy volunteers in February, and final study report in May 2023, as well as the development and the licensing deal with Alkem September 2023.